Additional treatment options impact first-line treatment of mRCC: Yes

Bookmark and Share
Published: 23 Sep 2014
Views: 2879
Prof Patrick Schöffski - University Hospitals Leuven, Leuven, Belgium

Prof Schöffski answers "yes" to the question "Have additional treatment options had a tangible impact on the first-line treatment of mRCC?" and tells us why.

He draws examples from the COMPARZ which showed that pazopanib had better scores than sunitinib for a number of clinically relevant domains and was preferred by patients.

GlaxoSmithKline fully provided for the costs of this symposium, honoraria for the chairs & speakers and provided input into the symposium agenda/content.